MX2022001038A - Métodos para tratar trastornos mediados por anticuerpos con antagonistas de fcrn. - Google Patents
Métodos para tratar trastornos mediados por anticuerpos con antagonistas de fcrn.Info
- Publication number
- MX2022001038A MX2022001038A MX2022001038A MX2022001038A MX2022001038A MX 2022001038 A MX2022001038 A MX 2022001038A MX 2022001038 A MX2022001038 A MX 2022001038A MX 2022001038 A MX2022001038 A MX 2022001038A MX 2022001038 A MX2022001038 A MX 2022001038A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- fcrn antagonist
- present disclosure
- antibodies
- provides methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962878541P | 2019-07-25 | 2019-07-25 | |
| PCT/US2020/043533 WO2021016571A2 (en) | 2019-07-25 | 2020-07-24 | Methods of treating antibody-mediated disorders with fcrn antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001038A true MX2022001038A (es) | 2022-04-26 |
Family
ID=72087159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001038A MX2022001038A (es) | 2019-07-25 | 2020-07-24 | Métodos para tratar trastornos mediados por anticuerpos con antagonistas de fcrn. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12655200B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4004039A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022542884A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220038432A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114466663B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020315925A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022001255A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3148764A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2022001164A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290101A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022001038A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202120539A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021016571A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023313033A1 (en) | 2022-07-27 | 2025-03-13 | Ablynx Nv | Polypeptides binding to a specific epitope of the neonatal fc receptor |
| US20240294651A1 (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
| IL322519A (en) | 2023-02-17 | 2025-10-01 | Ablynx Nv | Polypeptides that bind to the neonatal fc receptor |
| US20250034260A1 (en) | 2023-07-05 | 2025-01-30 | Sanofi | Fcrn antagonists for treatment of igg-related diseases and disorders |
| TW202525845A (zh) | 2023-08-23 | 2025-07-01 | 法商賽諾菲公司 | 基於ctla—4之溶體降解劑及其用途 |
| WO2025088546A1 (en) | 2023-10-25 | 2025-05-01 | Ablynx N.V. | Fc domain variants with enhanced fc receptor binding |
| IL328245A (en) | 2023-11-08 | 2026-07-01 | Sanofi Sa | CD25-based lysosomal compartment and its uses |
| AU2024413168A1 (en) * | 2023-12-27 | 2026-07-16 | Vetmab Biosciences, Inc. | FcRn ANTAGONISTS FOR VETERINARY USE |
| WO2026133288A2 (en) | 2024-12-20 | 2026-06-25 | Sanofi | IL-2RβΥ BASED LYSOSOMAL DEGRADER AND USES THEREOF |
| WO2026133294A1 (en) | 2024-12-20 | 2026-06-25 | Sanofi | Pd-1/gitr multispecific binding polypeptides and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU2001270609A1 (en) | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| BRPI0406605B8 (pt) | 2003-11-13 | 2021-05-25 | Hanmi Holdings Co Ltd | conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo |
| JP4762156B2 (ja) | 2004-01-12 | 2011-08-31 | アプライド モレキュラー エボリューション,インコーポレイテッド | Fc領域変異体 |
| BRPI0514068B8 (pt) | 2004-08-04 | 2021-05-25 | Applied Molecular Evolution Inc | anticorpo anti-cd20, e, composição farmacêutica |
| CA2577133A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US9200079B2 (en) * | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| WO2006130834A2 (en) * | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| AU2009303526B2 (en) | 2008-10-14 | 2015-01-15 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| ES2573642T3 (es) | 2009-12-23 | 2016-06-09 | Synimmune Gmbh | Anticuerpos anti-FLT3 y métodos de usar los mismos |
| WO2011089211A1 (en) | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| MX2013011366A (es) * | 2011-03-30 | 2014-05-12 | Chugai Pharmaceutical Co Ltd | Retencion de las moleculas de union al antigeno en el plasma sanguineo y metodo para modificar la inmunogenicidad. |
| GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| TW201817745A (zh) * | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| CA2871934C (en) | 2012-04-30 | 2023-06-13 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| CA2904805A1 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| CA2904806C (en) | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
| CN106103476B (zh) | 2013-12-24 | 2020-11-27 | 阿尔金克斯有限公司 | FcRn拮抗剂及使用方法 |
| US20170211876A1 (en) | 2014-06-12 | 2017-07-27 | Hoffmann-La Roche Inc. | Method for selecting antibodies with modified fcrn interaction |
| RU2713131C1 (ru) | 2014-11-06 | 2020-02-03 | Ф. Хоффманн-Ля Рош Аг | ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А |
| PT3215528T (pt) * | 2014-11-06 | 2019-10-11 | Hoffmann La Roche | Variantes da região fc com ligação modificada ao fcrn e métodos de utilização |
| SG11201702550WA (en) | 2014-11-10 | 2017-04-27 | Hoffmann La Roche | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| MX386491B (es) * | 2015-03-09 | 2025-03-18 | argenx BV | Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn. |
| CA3022547A1 (en) | 2015-05-12 | 2016-11-17 | Syntimmune, Inc. | Humanized affinity matured anti-fcrn antibodies |
| CA3032820A1 (en) | 2016-08-02 | 2018-03-22 | Visterra, Inc. | Engineered polypeptides and uses thereof |
| GB201618424D0 (en) * | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
| WO2018213097A1 (en) * | 2017-05-15 | 2018-11-22 | University Of Rochester | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof |
| MA51032A (fr) * | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| BR112020015006A2 (pt) * | 2018-01-26 | 2020-12-29 | Genzyme Corporation | Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada |
-
2020
- 2020-07-24 CN CN202080067562.1A patent/CN114466663B/zh active Active
- 2020-07-24 MX MX2022001038A patent/MX2022001038A/es unknown
- 2020-07-24 US US16/938,727 patent/US12655200B2/en active Active
- 2020-07-24 AU AU2020315925A patent/AU2020315925A1/en active Pending
- 2020-07-24 CA CA3148764A patent/CA3148764A1/en active Pending
- 2020-07-24 TW TW109125184A patent/TW202120539A/zh unknown
- 2020-07-24 JP JP2022504569A patent/JP2022542884A/ja active Pending
- 2020-07-24 WO PCT/US2020/043533 patent/WO2021016571A2/en not_active Ceased
- 2020-07-24 KR KR1020227005875A patent/KR20220038432A/ko active Pending
- 2020-07-24 EP EP20757029.2A patent/EP4004039A2/en active Pending
- 2020-07-24 BR BR112022001255A patent/BR112022001255A2/pt unknown
- 2020-07-24 CN CN202511907105.XA patent/CN122272792A/zh active Pending
-
2022
- 2022-01-24 IL IL290101A patent/IL290101A/en unknown
- 2022-02-04 CO CONC2022/0001164A patent/CO2022001164A2/es unknown
-
2025
- 2025-03-26 JP JP2025051382A patent/JP2025098167A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2022001164A2 (es) | 2022-03-08 |
| JP2025098167A (ja) | 2025-07-01 |
| IL290101A (en) | 2022-03-01 |
| EP4004039A2 (en) | 2022-06-01 |
| TW202120539A (zh) | 2021-06-01 |
| CN114466663A (zh) | 2022-05-10 |
| US20210024620A1 (en) | 2021-01-28 |
| US12655200B2 (en) | 2026-06-16 |
| WO2021016571A3 (en) | 2021-03-04 |
| KR20220038432A (ko) | 2022-03-28 |
| JP2022542884A (ja) | 2022-10-07 |
| CA3148764A1 (en) | 2021-01-28 |
| CN114466663B (zh) | 2026-01-02 |
| WO2021016571A2 (en) | 2021-01-28 |
| CN122272792A (zh) | 2026-06-26 |
| AU2020315925A1 (en) | 2022-03-03 |
| BR112022001255A2 (pt) | 2022-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022001164A2 (es) | Métodos para tratar trastornos mediados por anticuerpos con antagonistas de fcrn | |
| BR112021014074A2 (pt) | Proteínas de ligação ao antígeno anti-receptor il2 gama | |
| CL2021003327A1 (es) | Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089). | |
| WO2021055253A3 (en) | Anti-tnfr2 antibodies and methods of use | |
| MX382284B (es) | Anticuerpo que se une a fcrn para usarse en el tratamiento de enfermedades autoinmunes. | |
| CR20210492A (es) | ANTICUERPOS CONTRA AMILOIDES-ß CON PIROGLUTAMATO Y USOS DE ESTOS | |
| EA202100199A1 (ru) | Моноклональные антитела, специфически связывающиеся с trbv-9 человека | |
| BR112012007365A2 (pt) | proteínas de ligação à il-1 | |
| JOP20210169B1 (ar) | أجسام مضادة أحادية النسيلة ضد منطقة سلسلة بيتا من trbv9 بشري | |
| GT200600182A (es) | Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos | |
| RU2015104760A (ru) | Связывающие kir3dl2 агенты | |
| AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
| AR117091A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| MX386491B (es) | Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn. | |
| NI202000051A (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
| WO2021048564A3 (en) | Antigen-binding domain | |
| MX2021012488A (es) | Receptores de antigeno quimerico del receptor 1 anti-folato humanizado y usos de los mismos. | |
| EP4613334A3 (en) | Her-2 binding antibodies | |
| MX2024008933A (es) | Anticuerpos anti-musk para uso en el tratamiento de trastornos neuromusculares. | |
| CO2025014358A2 (es) | Unión de anticuerpos al dominio similar a la proteasa del receptor de transferrina humana htfr1 | |
| US20220169747A1 (en) | Anti-her2 binding molecules | |
| PH12019550203A1 (en) | Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour | |
| MX2022004058A (es) | Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo. | |
| DE102010024636B4 (de) | Antikörper, insbesondere für die Diagnostik | |
| WO2023004036A3 (en) | Anti-fsh antibodies for neurodegenerative diseases |